<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01839877</url>
  </required_header>
  <id_info>
    <org_study_id>FFCD 1201 DEBIRI</org_study_id>
    <nct_id>NCT01839877</nct_id>
  </id_info>
  <brief_title>Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study</brief_title>
  <official_title>Intra-arterial Hepatic Beads Loaded With Irinotecan With Concomitant Chemotherapy With FOLFOX in Patients With Colorectal Cancer With Unresectable Liver Metastases: a Phase II Multicenter Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Federation Francophone de Cancerologie Digestive</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Biocompatibles UK Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Federation Francophone de Cancerologie Digestive</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Treatment of patients with colorectal cancer having liver metastases is currently based on&#xD;
      systemic chemotherapy.&#xD;
&#xD;
      Triple therapy with 5FU, oxaliplatin and irinotecan intravenously was effective in terms of&#xD;
      response and secondary resectability, however it is particularly toxic.&#xD;
&#xD;
      Hepatic intra-arterial chemotherapy (HIA) has been the subject of several studies. It has&#xD;
      shown good efficacy with oxaliplatin and FUDR. However, the procedure is difficult to set up&#xD;
      and reserved for experienced centers.&#xD;
&#xD;
      The objective of this protocol is to use a triple therapy based on 5FU and oxaliplatin&#xD;
      associated to irinotecan which is administered by hepatic intra-arterial route, loaded onto&#xD;
      microbeads (DEBIRI). Furthermore, the procedure for chemo-embolization DEBIRI is limited to 2&#xD;
      sessions, and therefore could be more easily generalized.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2013</start_date>
  <completion_date type="Actual">January 2019</completion_date>
  <primary_completion_date type="Actual">December 2017</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate at 9 months</measure>
    <time_frame>at 9 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>safety of the study treatment</measure>
    <time_frame>at 9 months after inclusion</time_frame>
    <description>Adverse event rate; all grade, grades 1-2 and grades 3-4</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>2 years after last patient in</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">58</enrollment>
  <condition>Colorectal Cancer With Non Resectable Hepatic Metastasis</condition>
  <arm_group>
    <arm_group_label>HIA DEBIRI + systemic FOLFOX</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Intra-arterial hepatic beads loaded with irinotecan with systemic FOLFOX</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>HIA DEBIRI + systemic FOLFOX</intervention_name>
    <arm_group_label>HIA DEBIRI + systemic FOLFOX</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically proven colorectal adenocarcinoma,&#xD;
&#xD;
          -  Liver metastases radiologically or histologically proven&#xD;
&#xD;
          -  At least one measurable liver lesions by RECIST v1.1&#xD;
&#xD;
          -  Age ≥ 18 years&#xD;
&#xD;
          -  WHO Index &lt; or = 2&#xD;
&#xD;
          -  Life expectancy ≥ 3 months&#xD;
&#xD;
          -  No extrahepatic disease except lung nodules if number &lt; or = 3 and size &lt; 10 mm each&#xD;
&#xD;
          -  Healthy liver &lt;60%&#xD;
&#xD;
          -  Primary tumor resected or still in place&#xD;
&#xD;
          -  No prior chemotherapy for metastases treatment (except a perioperative chemotherapy,&#xD;
             if the last cycle was administered at least 12 months ago)&#xD;
&#xD;
          -  Adjuvant chemotherapy after resection of the primary authorized if the last cycle was&#xD;
             administered at least 12 months ago&#xD;
&#xD;
          -  Normal hepatic function: total bilirubin ≤ 1.5 N; AST ≤ 5N; ALT ≤ 5N and PAL ≤ 5N&#xD;
&#xD;
          -  TP ≥ 60%&#xD;
&#xD;
          -  Adequate hematologic function: ANC ≥ 1500/mm3, platelets ≥ 100 000/mm3, Hb ≥ 9g/dl&#xD;
&#xD;
          -  Good renal function: creatinine clearance ≥ 60 mL / min&#xD;
&#xD;
          -  No cardiac dysfunction: no cardiovascular events in the last 6 months or no NYHA ≥ 2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patient eligible for curative treatment (resection and / or radiofrequency ablation)&#xD;
             by a multidisciplinary decision (including the opinion of a liver surgeon)&#xD;
&#xD;
          -  Pregnant or lactating woman or patients of both sexes and of childbearing age not&#xD;
             using adequate contraception&#xD;
&#xD;
          -  History of cancer, except skin cancer (other than melanoma), carcinoma in situ of the&#xD;
             cervix uteri treated curative. Other cancers treated with curative intent are&#xD;
             permitted provided they did not relapse over the last 5 years&#xD;
&#xD;
          -  Peripheral neuropathy&#xD;
&#xD;
          -  Inflammatory Bowel Diseases&#xD;
&#xD;
          -  Intestinal obstruction&#xD;
&#xD;
          -  Chronic liver disease (viral, alcoholic or metabolic)&#xD;
&#xD;
          -  Immune Deficiency Syndromes (history of transplantation, infection with HIV)&#xD;
&#xD;
          -  Known to have contraindications to 5FU, oxaliplatin, folinic acid, irinotecan or to&#xD;
             contrast products&#xD;
&#xD;
          -  Patients with known contraindications against hepatic embolization procedures:&#xD;
&#xD;
        Presence of biliary-digestive anastomosis or biliary stent Cruoric or tumor thrombosis of&#xD;
        the portal vein&#xD;
&#xD;
          -  Patient who for psychological, social, family or geographical reasons could not be&#xD;
             followed up regularly&#xD;
&#xD;
          -  Legal disability (persons deprived of liberty or under guardianship)&#xD;
&#xD;
          -  Patient is not affiliated to a social security scheme&#xD;
&#xD;
          -  Participation in another concurrent study investigating the effect of treatment and&#xD;
             this until 4 weeks after the end of the concurrent study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Julien TAIEB, Pr</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fédération Francophone de Cancérologie Digestive</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hopital Saint André</name>
      <address>
        <city>Bordeaux</city>
        <zip>33075</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU - Hôpital François Mitterand</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Prive Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69008</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Léon Berard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU de la TIMONE</name>
      <address>
        <city>Marseille</city>
        <zip>13385</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Europeen G Pompidou</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHU Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hôpital Rangueil</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <results_reference>
    <citation>Pernot S, Pellerin O, Artru P, Montérymard C, Smith D, Raoul JL, De La Fouchardière C, Dahan L, Guimbaud R, Sefrioui D, Jouve JL, Lepage C, Tougeron D, Taieb J; for FFCD1201-DEBIRI investigators/Collaborators. Intra-arterial hepatic beads loaded with irinotecan (DEBIRI) with mFOLFOX6 in unresectable liver metastases from colorectal cancer: a Phase 2 study. Br J Cancer. 2020 Aug;123(4):518-524. doi: 10.1038/s41416-020-0917-4. Epub 2020 Jun 8.</citation>
    <PMID>32507854</PMID>
  </results_reference>
  <verification_date>December 2020</verification_date>
  <study_first_submitted>April 12, 2013</study_first_submitted>
  <study_first_submitted_qc>April 24, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 25, 2013</study_first_posted>
  <last_update_submitted>December 21, 2020</last_update_submitted>
  <last_update_submitted_qc>December 21, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Metastatic colorectal Cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Neoplasm Metastasis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

